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The fifth component of complement (C5)t is a 210,000-mol wt plasma glycoprotein 
comprised of two polypeptide chains  (a and ~  that are linked together by disulfide 
bonds and noncovalent interactions  (1). The C5 a  and/~ subunits  possess molecular 
weights of 115,000 and 75,000, respectively (2). Upon activation of either complement 
reaction  sequence  the  C5  convertase  enzymes,  C4b,2a,3b  (3-5)  or  C3bnBb,P  (6), 
hydrolyze a  specific peptide bond within the C5 a-chain resulting in the production 
of C5a  and  C5b  fragments.  The  smaller  C5a  fragment  (C5a  anaphylatoxin)  is  a 
cationic peptide derived from the first  74 amino acid residues of the amino-terminus 
of the C5 a-subunit  (2,  7-10).  The primary amino acid sequence of human  (11,  12) 
and porcine  (13,  14)  C5a has been determined.  The C5a anaphylatoxin  expresses a 
wide variety of biological activities including  (a)  contraction of smooth muscle  (15- 
18),  (b)  degranulation  of mast  cells  (7,  19),  (c)  chemotaxis  of polymorphonuclear 
neutrophils  (PMN)  (7,  18, 20, 21), and (at) secretion of azurophilic granular enzymes 
from PMN  (22-26).  Expression of C5a biological activity is regulated  by the endog- 
enous plasma enzyme carboxypeptidase N  (E.C.3.4.12.7), which rapidly removes the 
carboxy-terminal  arginine  from  C5a,  producing  the  C5a  des  Arg  derivative  that 
exhibits  greatly reduced activity (25-27).  The restricted  C5a des Arg anaphylatoxin 
activity can be enhanced by a  serum-derived "cochemotaxin" (28, 29), or in the case 
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of human C5a des Arg, by removal of the oligosaccharide moiety (30, 31). 
A  number  of physiologically  relevant,  non-complement-related,  proteolytic  en- 
zymes also are able to activate C5  to express C5a-like biological activities that can 
initiate or potentiate acute inflammatory reactions. For example, trypsin (21, 32-34), 
a-thrombin (35), elastase (36), and cathepsin G  (37)  can modify C5 to express PMN 
chemotactic and lysosomal enzyme-releasing activities. Since these enzymes are able 
to  activate C5  to express  biological activities that  are  indistinguishable  from C5a- 
mediated reactions, most investigators have concluded that noncomplement protease 
enzymes produce C5a,  or a  C5a-related  fragment, which  is released  subsequent  to 
limited hydrolysis of C5  (15,  22,  35).  However, our recent  reports  (38,  39)  indicate 
that limited trypsin digestion of C5 resulted in the expression of C5a-like biological 
activities without  the production of C5a and C5b fragments. To further document 
and  characterize  the  mechanism  by  which  noncomplement  enzymes  are  able  to 
activate C5 to express C5a-like biological activities, we report that  (a) the first C5a- 
chain site of trypsin hydrolysis is responsible for the activation of C:5 to express human 
neutrophil chemotaxis and lysosomal enzyme-releasing activity, (b)  the trypsin-acti- 
vated form of C5, which has a molecular weight of 210,000, retains biological activity 
even after preincubation and gel filtration column chromatography in the presence of 
sodium dodecyl sulfate (SDS),  (c)  a-thrombin, elastase, and plasmin also are able to 
activate C5 to express PMN lysosomal enzyme-releasing activity, and  (d)  the mech- 
anism of C5 activation by a-thrombin is similar to the novel activation mechanism 
described for trypsin. 
Materials and Methods 
Purified Complement Components and Reagents 
PURIFIED HUMAN C5.  Highly purified  C5  was  isolated  from outdated  human  plasma as 
described previously (40) with the following modifications. Instead of using QAE-Sephadex as 
the final chromatographic step, the contaminant proteins present in the C5 preparations after 
anti-Cl5  immunoadsorbent column chromatography were removed after dialysis  by passage 
through an anti-C5 impurities immunoadsorbent column as similarly described for the isolation 
of C6 (41). Antisera to contaminant proteins present in the C5 preparations (anti-impurities 
antisera) were raised in goats by injection of the C5-depleted, nonadsorbed protein fractions 
obtained after passage of the resuspended 37% ammonium sulfate precipitate of normal human 
serum (NHS) (C5 starting material) through the anti-C5 immunoadsorbent column. The IgG 
fraction from 500 ml of anti-impurities antisera was prepared by standard procedures (42) and 
covalently coupled to CNBr-activated Sepharose CL-4B at 30 mg of IgG/ml of beads by a 
modification of the procedure of March et al. (43) as described by Kolb et al. (44). 
RADIOIODINATION. High  purified human  C5  was radiolabeled with  NaX2~I by the solid- 
phase, mixed glucose oxidase,  lactoperoxidase procedure as described previously-(38). 
AFFINITY  PURIFICATION OF  CAPRINE  ANTI-HUMAN  C5  ANTIBODIES.  The C5 immunoadsorbent 
was prepared by covalently coupling 25 mg of highly purified human C5 to CNBr-activated 
Sepharose CL-4B at 1 mg Cl5/ml of beads as described previously (44). 50 ml of monospecific 
caprine anti-human C5 (IgG) was applied to the C5 immunoadsorbent column at a flow rate 
of 1 ml/h. The column was washed with 50 ml phosphate-buffered saline  (PBS) containing 10 
mM EDTA (PBSE)  followed by 50 ml PBSE containing 2 M NaCI at a flow rate of 5 ml/h. 
The anti-C5 antibodies were eluted with 25 ml of 0.2 M  sodium phosphate buffer, pH 6.0, 
containing 2 M KSCN at a flow rate of 20 ml/h collecting 2-ml fractions. The affinity-purified 
anti-C5  antibody  containing  fractions  were  pooled,  exhaustively  dialyzed  against  Hanks' 
balanced salt solution (HBSS), concentrated by positive pressure uhrafihration, filter sterilized, 
and stored at -70°C in 100-#1 portions. 
PROTEASES.  Human plasmin, kallikrein,  and elastase,  as well as bovine pancreatic trypsin WETSEL AND KOLB  2031 
were purchased from Sigma Chemical Co., St. Louis, MO. Highly purified human a-thrombin 
was provided by Dr. J. W. Fenton (New York State Dept  of Health, Albany, NY)  (45). The 
trypsin  was purified  further by affinity column chromatography as described by Robinson et 
al.  (46), as modified  by Wetsel  and  Kolb  (38). After elution  from  the affinity  column,  the 
trypsin was dialyzed against  1 mM HC1 and stored at -70°C. 
SDS-Polyacrflamide Slab Gel Electrophoresis.  Polyacrylamide  slab  gel  electrophoresis  in  the 
presence  of SDS  (SDS-PAGE)  was  conducted as  described  by Laemmli  (47) using  a  5% 
acrylamide stacking  gel. Nonreduced samples were run on 7% acrylamide running gels and 
reduced samples were run in the presence of 1% fl-mercaptoethanol  (tiME) on 10% acrylamide 
running gels. After electrophoresis,  the slab  gels were fixed in  10%  trichloroacetic  acid-20% 
methanol, stained  in  25% methanol-10%  acetic  acid containing 0.25% Coomassie Blue, and 
destained  in 10% isopropanol-10% acetic acid. 
The C5 a-chain fragments,  generated  by trypsin  cleavage, were quantitated from reduced 
SDS-PAGE slab gels using a Helena Quick-Scan R and D electrophoresis densitometer  (Helena 
Laboratories,  Beaumont, TX). The peak areas of stained  C5 a-chain fragment  protein  bands 
were calculated by using a Carl Zeiss MOP-3 digitometer.  Corrections for small differences in 
the amount of protein applied  to each gel lane were made by normalizing  the relative molar 
amounts of C5 a-chain fragments  in each  lane  to the relative  molar amount of C5 fl-chain 
present  in each lane. 
Isolation of Human Polymorphonaclear Neutrophils.  Human  polymorphonuclear neutrophils 
(PMN)  were isolated from healthy volunteers by the procedure of Boyfim (48) with modifica- 
tions as described previously (38). 
Polymorphonuclear Neutrophil Chemotaxis and Lysosomal Enzyme-releasing Assays.  Protease-acti- 
vated human C5 was assayed for PMN chemotactic and lysosomal enzyme-releasing activities 
as described previously (38). 
Protein Determinations.  Protein concentrations  of purified human C5 were determined  by the 
Folin procedure of Lowry et al. (49) using a C3 standard curve. Protein  concentrations  of the 
purified  trypsin  solutions  were  determined  spectrophotometrically  at  280  nm  utilizing  an 
E~cm  of 15.4 (46). 
Results 
Expression of C5a-Like  Biological Activity by To~psin-modified C5 
DEPENDENCE  ON  THE  MOLAR  CONCENTRATION  OF  C5  IN  THE  C5  ACTIVATION 
MIXTURE.  Increasing molar concentrations of C5 were incubated with a  fixed molar 
ratio of affinity-purified trypsin  (0.008 mol trypsin/mol C5)  in VB at  37°C  for 30 
rain.  Portions of each sample were  removed, diluted  in  HBSS containing  1 g/liter 
bovine  serum  albumin  (HBSS-0.1%  BSA)  containing  l0  #g/ml  soybean  trypsin 
inhibitor (SBTI), and 0.5 #g of trypsin-digested C5 from each dilution was assayed in 
duplicate for PMN lysosomal enzyme-releasing activity as described in Materials and 
Methods. As illustrated in Fig.  1, the amount of lysosomal enzyme-releasing activity 
generated by trypsin activation of  C5 was dependent upon the C5 molar concentration 
present in the initial digestion reaction. Maximum lysosomal enzyme-releasing activity 
was generated when C5 was present in the proteolysis reaction mixture at a  concen- 
tration of 5 x  l0  -s M  (1 mg/ml). C5 concentrations less than or greater than 5 X  l0  -s 
M  resulted  in  decreased  activity,  presumably  due  to  insufficient  or  excessive  C5 
hydrolysis, respectively. Therefore, unless stated otherwise, all subsequent C5 activa- 
tion assays used  1 mg C5/ml of VB at 37°C for 30 rain. 
DOSE RESPONSE.  Highly purified human C5 (1 mg/ml) was incubated with 0.008 
tool  of trypsin/tool  C5  as  described  above.  After  a  30-min  incubation  at  37°C, 
samples were removed and serially diluted in either HBSS-0.1% BSA containing l0 
#g SBTI/ml or HBSS-0.3% B SA containing 10 #g SBTI/ml. Increasing concentrations 2032 
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Fxo.  1.  Determination of the C5 molar concentration required for optimal activation by trypsin. 
Purified human C5, at the indicated molar concentrations, was incubated with a  constant molar 
ratio of trypsin as detailed in the text. After activation, 0.5 #g of each trypsin-digested C5 incubation 
mixture was assayed for PMN lysosomal enzyme-releasing activity. 
of  trypsin-activated  C5  were  assayed  for  PMN  lysosomal  enzyme-releasing  and 
chemotactic  activities  as  outlined  in  Materials  and  Methods.  The  results  (Fig.  2) 
indicated that trypsin-treated C5 effected the release of PMN lysosomal enzymes in 
a  dose-dependent manner over a concentration range of 1 ×  10  -12 to 10 ×  10  -12 mol 
per assay mixture (4 ×  106 PMN). However, a linear dose response was demonstrated 
only at inputs of trypsin-activated C5 <3 ×  10  -12 mol (0.6 #g)  (Fig. 2, panel A). The 
chemotaxis  assay  proved  to  be  more  sensitive  with  trypsin-activated  C5  effecting 
PMN chemotaxis in a  dose-dependent  manner over a  concentration  range of 0.5  × 
10  -13 to 10 X  10  -13 mol per assay chamber (1 ×  106 PMN). A linear dose response was 
demonstrated only at inputs of trypsin-activated C5 <3 x  10  -x3 mol (0.06/xg)  (Fig. 2, 
panel  B).  Therefore,  unless  stated  otherwise,  subsequent  PMN  lysosomal enzyme- 
releasing and chemotactic assays were monitored in their linear dose response ranges 
by utilizing 0.5 or 0.05 #g of trypsin-activated C5 per assay, respectively. 
SITE  OF  C5  a-CHAIN  HYDROLYSIS  GENERATING  BIOLOGIC  ACTIVITY.  Highly purified 
human C5 was incubated with affinity-purified trypsin  (0.008 mol trypsin/mol C5) 
at 37°C at a final C5 concentration of I mg/ml isotonic veronal-buffered saline (VB). 
After various time intervals, triplicate samples were collected simultaneously.  Phen- 
ylmethylsulfonyl fluoride (PMSF)  was immediately added to the first set of samples WETSEL  AND  KOLB  2033 
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FIG.  2.  Dose  response  assays of C5  activated by trypsin  under optimal conditions. Increasing 
concentrations of C5 activated by trypsin under optimal incubation conditions, as determined from 
the results in Fig. 1, were assayed for the ability to mediate neutrophi] |ysosoma] enzyme secretion 
and chemotaxis as outlined in  Materials and Methods. Undigested C5 expressed no  biological 
activity over the concentration ranges examined. 
(10/xl each) to a final concentration of 2.5 mM, and after collection of all time points, 
this first set of samples was analyzed by SDS-polyacrylamide slab gel electrophoresis 
under reducing conditions. To substantiate the ability of PMSF to completely inhibit 
trypsin digestion, PMSF was added to highly purified C5  (1 mg/ml VB)  to a  final 
concentration of 2.5 mM before the addition of trypsin (0.008  mol trypsin/mol C5), 
which was followed by a 30-min incubation at 37°C and SDS-PAGE analysis (Fig. 3, 
upper panel, lane C). After protein staining with Coomassie Blue, the SDS-polyacryl- 
amide slab  gels were analyzed on a  scanning densitometer and the relative molar 
amounts of the trypsin-produced C5 al-chain fragment, as defined previously (38), 
were quantitated and normalized by the molar amount of C5 fl-chain present in each 
gel lane as outlined in Materials and Methods. The second set of time point samples 
(5/d each) were diluted immediately into 3 ml of HBSS-0.1% BSA containing 10 #g 
SBTI/ml,  and  2.4  ×  10  -12  mol  (0.5  #g)  of C5  from each were assayed for PMN 
lysosomal enzyme-releasing activity. The third set of time point samples (5 #1 each) 
were diluted immediately into 3 ml of HBSS-0.3% BSA containing 10 #g SBTI/ml, 
and 2.4 X  10  -la mol (0.05 #g) of C5 from each were assayed for PMN chemotaxis. As 
seen in Fig. 3, the first trypsin-mediated C5 cleavage event, i.e., C5 a-chain conversion 
to C5al and C5a5 (C5') was responsible for activating trypsin-treated C5 to express 
both PMN lysosomal enzyme-releasing and chemotactic activities. 
The  Question of a  Released  Fragment(s) from  Trypsin-modified  C5 Expressing  C5a-Like 
Biological Activity 
KINETICS OF C5 ACTIVATION BY TRYPSIN.  TO examine the possible production and 
release of a biologically active fragment from trypsin-modified 125, the kinetics of 125 
activation by trypsin was determined. Highly purified human C5 at a concentration Flo.  3.  Correlation between the site of C5 a-chain cleavage and acquisition of biological activity. 
Highly purified C5 was incubated at 37°C with 0.008 mol trypsin/tool C5 at a final C5 concentration 
of I mg/ml (5 ×  10  -6 M). Samples were removed at the indicated time intervals and the amount of 
C5 a-chain hydrolysis (A)  and PMN lysosomal enzyme-releasing and ehemotaetie activities were 
quantitated  as outlined in the text.  In B, the percent of maximum C5al  fragment produced, N- 
acetyl-fl-glucosaminidase released, and chemotactic activity generated were plotted as a function of 
time. When the relative amounts of biological activity generated were plotted as a  function of the 
relative molar amounts of the C5al fragment produced at each time point, correlation coefficients 
of 0.960  and 0.945  were  obtained  for the PMN  chemotactic and enzyme releasing activity plots 
respectively ( B, inset). 
2034 WETSEL AND KOLB  2035 
of 1 mg/ml VB was incubated with 0.03 mol of affinity-purified  trypsin/mol of C5 at 
37°C. After various time intervals, 5-#1 samples were diluted into 3 ml of HBSS-0.1% 
BSA containing 10 #g SBTI/ml, and 2.4 ×  10  -12 mol (0.5/Lg) of each trypsin-treated 
sample were assayed for PMN lysosomal enzyme-releasing activity. Detectable lyso- 
somal enzyme-releasing activity was observed after 1 rain of incubation, and 100% of 
maximum activity was  generated after 20  min of incubation.  Incubation periods 
longer than 20 rain resulted in a time-dependent decrease in the expression of trypsin- 
modified C5 biological activity with only 10% of maximum activity remaining after 
150 rain (data not shown). 
GEL  FILTRATION  AT  PHYSIOLOGIC  IONIC  STRENGTH,  pH  7.4.  2  mg of 125I-C5  were 
incubated with 0.03 mol trypsin/tool C5 in a final volume of 2 ml VB at 37°C for 20 
min, which resulted in the expression of 100% of maximum PMN lysosomal enzyme- 
releasing activity as outlined above.  Another 2-mg sample of 125I-C5 was incubated 
with 0.03 tool trypsin/tool C5 in a  final volume of 2 ml VB at 37°C for 100 rain, 
which resulted in the expression  of only 30% of maximum PMN lysosomal enzyme- 
releasing activity due to excessive trypsin-digestion. Both trypsin-activated 125I-C5 
samples  were  made  2.5  mM  in  PMSF  and  subjected  to  Biogel  P-200  (Bio-Rad 
Laboratories, Richmond, CA) gel filtration column chromatography. As seen in Fig. 
4, panel A, the trypsin-activated 125I-C5 sample expressing  100% of maximum activity 
eluted at the same Ve/Vt as native 125I-C5 with a corresponding molecular weight of 
210,000.  In addition, all detectable PMN lysosomal enzyme-releasing activity was 
associated  with  only  the  high  molecular  weight,  trypsin-modified C5-containing 
fractions. However, the excessively digested 125I:C5 sample expressing  only 30%  of 
maximum activity yielded two additional C5-derived fragment peaks with molecular 
weights of -  15,000 and 5,000 (Fig. 4, panel B). Although the 15,000 molecular weight 
fragment expressed  a  limited amount of lysosomal  enzyme-releasing activity when 
300-~1 portions of the column fractions were assayed (six times the volume routinely 
employed), over  95%  of the  C5a-like  biological  activity was  associated  with  the 
210,000 molecular weight form of trypsin-activated C5. 
The extent of C5 digestion that had occurred in these experiments was determined 
upon  SDS-polyacrylamide slab  gel  analysis of the  210,000 molecular weight peak 
fractions obtained from the two column profiles  presented in  Fig.  4  as  indicated. 
Under nonreducing conditions (Fig. 5, left), the trypsin-treated C5 expressing  100% of 
maximum activity (pool A)  ran as a  single  protein band with the same molecular 
weight as native C5, while the trypsin-treated C5 expressing 30% of maximum activity 
(pool B)  was hydrolyzed more extensively as evidenced by the presence  of C5I and 
C5II  fragments,  as  defined  previously  (38). Upon  reduction  (Fig.  5,  right),  the 
biologically active form of the trypsin-activated C5  expressing  100% of maximum 
activity (pool A) was determined to be C5' since 78 ±  5% of the C5 a-chain derived 
protein was present as C5al and C5t~. In contrast, the extensively trypsin-digested C5 
expressing  only 30% of maximum activity (pool B) was devoid of a C5al fragment, 
which had been hydrolyzed completely to C5a2 and C5a4. Quantitative densitometric 
scans of these gels indicated the relative molar amount of C5a5 fragment present in 
the trypsin-treated C5 expressing  30% of maximum activity was -30% of the molar 
amount  of C5a5  fragment  present  in  the  trypsin-treated C5  expressing  100% of 
maximum activity. Therefore, these results  strongly suggested  that the determining 
factor required for the expression of C5a-like biological activities by trypsin-modified 2036  EXPRESSION  OF  CSa-LIKE  ACTIVITIES  BY  HUMAN  C5 
I 
(2_  # 
x  ÷ 
o 
(.3 
It) 
(.3 
V  o  _  68  30  12,5  6  -& 
5.0-  12 
Ii 
! 
2.5.  I0 
2.0, 
1.5. 
.g 
as  ~ 
'F: 
0 J  -  -  0  "~ 
6  '  o'.2  ........  04  06  o8  ,.0 
~o  68  30  12.5  6  B 
I  1  1  1  - 
3.0-  -12 
2.5-  -I0 
A 
f  q 
2.0-  i  -8 
P 
I 
1.5-  I  -6  i 
i  i 
i 
I.o  ~  -4 
!  !  ~  i  ! 
b  '  0'.2  0:4  o:6  0.8  Lo 
V,/VT 
FIG.  4.  Gel filtration  column  chromatography at pH  7.4 of trypsin-activated C5, Human C5 was 
digested with trypsin for 20 rain (A,  100% of maximum activity) or 100 rnin (B, 30% of maximum 
activity) as described in the text and subjected to gel filtration column chromatography using Biogel 
P-200. The column (1.5  X 60 cm) was equilibrated with PBS and 500-#1 samples were collected at 
a  flow rate of 4  ml/h at 4°C. 50-#1 portions from the indicated fractions were assayed for PMN 
lysosomal enzyme-releasing activity. Molecular weight estimates were determined by utilizing the 
following reference markers and indicated mol wt values (X 10a): thyroglobulin (void volume, Vo), 
BSA (68), carbonic anhydrase (30), cytochrome C (12.5), aprotinin (6) and phenol red (total volume, 
Vv). 
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FIc.  5.  SDS-polyacrylamide slab  gel  electrophoresis. The  210,000 mol  wt  biologically active 
fractions obtained subsequent  to gel filtration analysis of trypsin-activated C5, as seen in Fig. 4, 
were pooled where indicated and subjected to SDS-polyaery|amide slab gel electrophoresis in the 
presence or ahzence of~ME as described in Materials and Methods. The pool obtained from Fig. 
4A, was derived from the C5 digest expressing 100% of maximum activity and is labeled Pool A. 
The pool obtained  from Fig. 4B, was derived from the C5 digest expressing 30% of maximum 
activity and is labeled Pool B. 
forms of C5 was the presence of the C5az fragment. 
GEL FILTRATION  OF TRYPSIN-ACTIVATED  C5 AT pH 4.0.  The results presented in Figs. 
4  and  5  do  not  support  the  previously  published  report  of Cochrane  and  Miiller- 
Eberhard  (15), which concluded that the only bio[og~cally active, C5-related compo- 
nent  produced  upon  trypsin  digestion  of human  C5  was  the  CSa  anaphylatoxin 
fragment,  as  demonstrated  upon  gel  filtration  column  chromatography  at  pH  4.0. 
Gel filtration was conducted at pH 4.0 in their studies to insure complete dissociation 
of noncovalently bound fragments from trypsin-activated (25 molecules.  In an effort 
to closely examine and perhaps  determine  the basis  for these apparently conflicting 
results, 3 mg of Iz51-C5 was incubated with 60/~g of trypsin (0.17 tool trypsin/tool C5) 
in  a  final  volume of 3  ml VB  at  32°C  for 5  rain.  These  activation  conditions  were 
selected  to approximate  those employed by Oochrane and  Miiller-Eberhard  (15)  as 
closely as possible.  The sample was made 2.5 mM in PMSF and adjusted  to pH 4.0 
by the slow dropwise addition of 2  N  HCL In the majority of experiments  (4/6), pH 
adjustment  to 4.0 resulted  in overt precipitation  of trypsin-activated C5. Analysis of 2038  EXPRESSION  OF  C5a-LIKE  ACTIVITIES  BY  HUMAN  C5 
precipitated or apparently nonprecipitated trypsin-activated C5 at pH 4.0 by Biogel 
P-200  gel  filtration column  chromatography  yielded similar  results.  Namely,  the 
210,000 molecular weight form(s) of trypsin-activated C5 was bound to or precipitated 
on the gel filtration column at pH 4.0 and could not be eluted  (Fig. 6).  However, 
minor  amounts  of 125I-C5 derived  fragments  of approximately  5,000  and  10,000 
molecular weight were eluted that expressed detectable levels of C5a-like biological 
activity only when 400-/d portions of the indicated fractions were assayed for PMN 
lysosomal enzyme-releasing activity; no C5a-like activity was demonstrable when 50- 
/~1 portions from these fractions, the volume normally employed to detect C5' activity 
(Fig. 4A and B), were assayed. 
ISOLATION OF TRYPSIN-ACTIVATED C5 IN THE PRESENCE OF SDS.  To further substantiate 
the conclusion that the predominant, biologically active form of trypsin-activated C5 
is  a  210,000  molecular weight, trypsin-modified C5  molecule (C5'-C5"  as defined 
previously [38]),  and to exclude the possibility that the biological activity expressed 
by trypsin-activated C5  was due primarily to the production of a  small molecular 
weight,  noncovalently bound  fragment(s)  that  could  be  slowly released,  trypsin- 
activated  C5  was  preincubated  with  SDS  and  subjected  to  gel  filtration column 
chromatography in the presence of SDS, a strong protein-denaturing and -dissociating 
detergent. 5 mg of 125I-C5 was incubated with 0.008 mol trypsin/mol C5 at 37°C for 
30 rain in a total volume of 5 ml VB. Trypsin was removed with chicken ovamucoid- 
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a  flow rate of 4 ml/h at 22°C. 400-#1 portions from the indicated fractions were assayed for PMN 
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Sepharose 4B  (46). SDS was added to the trypsin-digested C5 supernatant  to a  final 
concentration  of 2%  (wt/vol), and incubated at  220C  for 60 min. The SDS-treated 
sample was concentrated  to  a  final  volume of 2  ml by ultrafiltration  employing a 
YM-5  Amicon membrane  (Amicon Corp.,  Scientific  Sys.  Div.,  Danvers, MA)  and 
subjected to gel filtration analysis utilizing a Sepharose CL-4B column (1.5 cm ×  120 
era)  equilibrated with PBS containing 0.2%  SDS.  As seen in Fig.  7, the majority of 
trypsin-activated 1~I-C5 eluted  from the  gel  filtration column  as a  high  molecular 
weight peak. A minor, lower molecular weight component was also evident ( Ve/Vt of 
0.81-0.84).  The  fractions  containing  the  high  molecular  weight  form  of trypsin- 
activated lz5I-C5 were pooled as indicated and analyzed by SDS-polyacrylamide slab 
gel electrophoresis (Fig. 7, inset).  Under nonreducing conditions the trypsin-activated, 
SDS-treated  and  gel-filtered  C5  exhibited  the  same  electrophoretic  mobility  and 
molecular weight  as  native,  undigested  C5  (Fig.  7  inset,  left  panel).  Analysis under 
reducing conditions indicated that trypsin-activated, SDS-treated and gel-filtered C5 
was predominantly in the C5' form since 80 :t: 5% of the C5 a-chain fragments (on a 
molar basis) were present as C5al and C5a5 fragments that were disulfide bonded to 
the C5' molecule (Fig. 7 inset, right panel). To verify that SDS-treated and gel-filtered 
Fio.  7.  Gel filtration column chromatography of trypsin-activated C5 in the presence of SDS. 
Human C5', prepared as described in the text, was preincubated with 2% SDS at 22°C for 60 min 
and subjected to gel filtration at a flow rate of 4 ml/h collecting 1-ml fractions at 22°C using a 
Sepharose CL-4B column (1.5 ×  120 cm) equilibrated with PBS containing 0.2% SDS. The major 
peak fraction was pooled as indicated and subjected to SDS-polyacrylamide  slab gel analysis in the 
presence (reduced) or absence (nonreduced)  of/~ME (inset). 2040  EXPRESSION  OF  C5a-LIKE  ACTIVITIES  BY  HUMAN  C5 
C5' still retained C5a-like biological activity, the 125I-C5' pool, as indicated in Fig. 7, 
was incubated at  2°C  for  1 h  to remove unbound SDS  by precipitation.  The C5' 
containing supernatant was dialyzed exhaustively against PBS, and assayed for C5a- 
like biological activity. As seen in Fig. 8, the SDS-treated  and gel-filtered C5' still 
retained the ability to mediate the release of lysosomal enzymes from human neutro- 
phils in a  dose-dependent manner after SDS removal. This activity was shown to be 
a property of the C5' molecule and not of residual detergent because lactate dehydro- 
genase  (LDH)  activity was  not  present  in  the  neutrophil  supernatants  (data  not 
shown),  and  immunoaffinity-purified goat  anti-human  C5  antibodies  completely 
blocked lysosomal enzyme-releasing activity (Fig.  8).  In addition, the SDS was also 
removed, as described above, from the pooled fractions containing the small molecular 
weight fragments produced upon trypsin digestion of 1~I-C5 (Fig.  7), and assayed for 
PMN lysosomal enzyme-releasing activity. It was estimated that after SDS removal 
only 10% of the total- recoverable C5a-like activity was expressed by the low molecular 
weight, C5-derived  fragments, while 90%  of the total recoverable C5a-like activity 
was  expressed  by the  210,000  molecular weight, C5'  form of trypsin-activated C5 
(data not shown). 
C5 Activation by  Various Noncomplement Enzymes.  5-/~g  portions of highly purified C5 
were  incubated  with  increasing  concentrations  of  trypsin,  a-thrombin,  plasmin, 
kallikrein,  or  elastase  (0.004-4  tool  protease/mol  C5)  for  30  rain  at  37°C  and 
subsequently analyzed for their ability to induce the release of N-acetyl-fl-glucosa- 
minidase  from PMN  lysosomes. As  illustrated in  Fig.  9,  C5  digested with  all  the 
proteases except kallikrein, effected the release of PMN azurophilic lysosomal enzymes 
in a  dose-dependent manner. Trypsin and elastase, under the incubation conditions 
employed,  activated  C5  to  express  biological  activity  at  relatively  low  protease 
concentrations with as little as 0.004 tool trypsin and 0.01  tool elastase per mol C5 
eliciting measurable  quantities of activity, a-Thrombin  at  a  concentration of 0.08 
mol/mol C5  and plasmin at a  concentration of 0.8 mol/mol C5 also exhibited the 
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Pza.  8.  Dose response of trypsin-activated C5' isolated in the presence of SDS. Human C5', which 
was SDS-treated, gel-filtered,  pooled, and dialyzed as detailed in the text, was assayed for PMN 
lysosomal enzyme-releasing activity at the indicated concentrations. Identical samples were prein- 
cubated for  1 h  at 22°C with a  50 molar excess of immunoadsorbent affinity-purified caprine anti- 
C5  antibodies  (Materials  and  Methods)  per  mole  C5'  and  monitored  for  remaining biological 
activity. 1  C5'. l--l, C5' +  anti-C5. WETSEL  AND  KOLB  2041 
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FIO.  9.  Activation oft5  upon limited digestion with various proteases. Human C5 was incubated 
with the indicated molar ratios of trypsin, (~-thrombin, plasmin, kallikrein or elastase, as detailed in 
the text, and assayed for the ability to induce the release of PMN lysosomal N-acetyl-fl-glueosamin- 
idase. •,  trypsin; 0, thrombin; A, plasmin; O, kallikrein; A, elastase; D, LDH. 
ability to generate enzyme-releasing activity from human C5. C5 alone, as well as the 
highest concentration of each protease employed alone, expressed no PMN lysosomal 
enzyme-releasing activity. 
Site of C5 a-Chain Hydrolysis Mediated by a-Thrombm.  Since previously published 
reports have indicated that o(-thrombin can activate human C5 to express C5a-like 
biological activity (35,  50),  it was of interest to determine the first site(s)  of C5-a 
chain hydrolysis mediated by a-thrombin.  Highly purified C5 was incubated with 
human a-thrombin  (1  mol a-thrombin/mol C5)  in  50  mM  Hepes buffer, pH  7.5 
containing 145 mM NaCI, 0.15 mM CaCI2, and 0.5 mM MgCI2 at 37°C for 20 h at 
a  C5  concentration of 0.5  mg C5/ml.  a-Thrombin  digestion was stopped  by the 
addition of PMSF to a final concentration of 2.5 mM, and the a-thrombin-treated C5 
was subjected to SDS-polyacrylamide slab gel eleetrophoresis in the presence of tiME. 
The results from this study, presented in Fig. 10A, indicated that limited a-thrombin 
and trypsin digestion of C5 resulted in similar C5  fragmentation profiles. Namely, 
a-thrombin also cleaved the C5  a-subunit  irito C5ax and C5as  fragments (labeled 
C5al  thr and C5a5  thr to distinguish them from the trypsin-produced fragments, C5al  t~y 
and CSastw).  Quantitative densitometric scans of these slab  gel  lanes  (Fig.  10, B) 
further illustrated that the first site of a-thrombin and trypsin cleavage of the C5a- 
chain were very similar. Furthermore, in analogy with trypsin activation, preliminary 
results have also suggested that the first a-thrombin-mediated fragmentation event 
that hydrolyzed the C5a chain to al  th~ and a5  t~ (C5'th~) activated C5 to express C5a- 
like biological activity (50). 2042  EXPRESSION  OF  (35a-LIKE  ACTIVITIES  BY  HUMAN  C5 
F1o.  10.  Direct comparison between a-thrombin and trypsin produced C5 fragmentation profiles 
as examined by SDS-polyacrylamide slab gel electrophoresis. Human (35 was subjected to limited 
a-thrombin or trypsin digestion followed by SDS-PAGE analysis in the presence of  tiME as outlined 
in the text (A). Densitometric scans were performed on the (3oomassie Blue-stained gels and are 
presented in B. The densitometric scans were oriented with respect to t25 a- and fl-chain mobilities. 
Discussion 
Several experimental variables were examined in an effort to maximize the ability 
of trypsin to activate human C5 to express C5a-like biological activities. When trypsin 
activation of (]5 was conducted under optimal conditions, the trypsin-modified C5 
mediated  the  directed chemotaxis  and  release of lysosomal  enzymes from  human 
neutrophils in a  linear dose-response manner over a  range of 0.1  ×  10  -12 to 0.3  × 
10  -12 tool per assay chamber and  1.0 ×  10  -12 to 3 ×  10  -12 mol per reaction mixture, 
respectively. In  addition, our previously published results indicated  that  the molar 
concentration of trypsin-activated C5 required to attain maximal PMN chemotaxis 
(3 ×  10  -12 mol) and lysosomal enzyme-releasing activity (4 ×  10  -11 to 8 ×  10  -11 mol) 
was  essentially  identical  to  the  concentration  of highly  purified  C5a  required  to 
mediate peak responses in  the same biological assay systems  (25, 26).  These results 
suggested that limited trypsin digestion of (]5 resulted in the production and release 
of the C5a anaphylatoxin fragment. This presumptive conclusion that the primary or 
preferred site of trypsin hydrolysis of C5 resulted in the production and release of C5a 
or a C5a-related fragment(s) has been further supported by other previously published 
reports. Thus, Cochrane and Miiller-Eberhard (15) clearly demonstrated that limited WETSEL AND KOLB  2043 
trypsin digestion of human  C5 resulted in the production of a  10,000 mol wt, C5- 
derived  fragment  upon  gel  filtration  column  chromatography  at  pH  4.0,  that  ex- 
pressed CSa-like biological activity. Ward and Newman (21), utilizing sucrose density 
gradient  ultracentrifugation,  reported the production of an 8,500 molecular weight 
chemotactic factor generated upon trypsin digestion of C5, and Goldstein et al. (32) 
employing gel filtration column chromatography, showed that trypsin digestion of C5 
yielded a  low molecular weight  fragment  expressing neutrophil  lysosomal enzyme- 
releasing activity. Therefore, the recently proposed hypothesis of Wetsel et al.  (38), 
which suggested the principle mechanism by which trypsin activated C5 to express 
C5a-like  biological  activity  does  not  require  the  release  of  a  biologically  active 
fragment(s), appears to be in direct conflict with these previously published results. 
Nevertheless, the results presented in the present study can reconcile these appar- 
ently conflicting observations. Collectively, all of the currently available data clearly 
indicates that  trypsin digestion of C5 can result in the production and release of a 
small molecular weight fragment(s), presumably C5a-related, which express a variety 
of phlogistic  activities.  However, under  optimal  activation  conditions  (0.008  mol 
trypsin/tool C5) <10% of the overall total C5a-like activity is represented by 5,000- 
15,000 molecular weight fragments  (Figs. 4 and  7). Furthermore,  the production of 
these 5,000-15,000 molecular weight fragments occurs only after extensive C5a-chain 
digestion,  and  the  quantity  of fragments  released cannot  be increased  even upon 
preincubation and gel filtration of trypsin-activated C5 in the presence of SDS (Fig. 
7). The trypsin digestion conditions utilized by Ward and Newman (21) and Goldstein 
et al.  (32) employed molar ratios of trypsin to C5 that  were  100-400 times greater 
than  necessary  for  optimal  C5  activation  (Figs.  1-3).  Their  digestion  reactions 
therefore clearly utilized trypsin molar ratios in excess of any physiologically relevant 
C5 activation conditions attainable  in vivo.  Nevertheless, both studies  (21, 38)  did 
demonstrate  the presence of uncharacterized,  biologically active  material  approxi- 
mating  native  C5  in  molecular weight  that  exhibited  C5a-like  biological activity. 
However, this high molecular weight form of trypsin-activated C5 was not observed 
in the studies of Cochrane and Miiller-Eberhard  (15) since it was precipitated on the 
gel filtration column upon acidification  (Fig.  6). Collectively, these previously pub- 
lished observations (21, 32, 38), in conjunction with the results presented in Figs. 3-5, 
and  7, indicate that  the primary and preferred site of trypsin cleavage on the C5a- 
chain results in the production of C5t~1 and CSa~ fragments that remain covalentty 
disulfide  bonded  to  the  modified  C5  molecule  (C5').  Furthermore,  this  primary 
trypsin-mediated cleavage event activates C5 to express C5a-like biological activity 
(Figs. 3 and  11). 
Trypsin activation of complement proteins, particularly C3 and C5, may contribute 
significantly to the nonimmunologic inflammatory reactions observed in acute pan- 
creatitis. Thus, the onset of acute pancreatitis is associated with a reduction in levels 
of total  complement  with  the  concomitant  appearance  of C3  fragments  in  the 
peripheral circulation  (51, 52). In addition, Jacob et al.  (53) have reported recently 
that the severe loss of vision, due to posterior retinal emboli of aggregated neutrophils, 
suffered by some patients with acute pancreatitis, was most likely mediated by trypsin- 
activated C5 since neutrophil  aggregation  induced  by these patients'  sera was in- 
hibited by anti-C5 antibodies. In view of the present report, one would predict that 
a large proportion of the C5a-like biologically active factor present in the circulation 2044  EXPRESSION  OF C5a-LIKE ACTIVITIES  BY  HUMAN  C5 
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FIG.  l 1.  A structural model illustrating the mechanism by which C5 can be activated to express 
C5a-like biological activities via two independent pathways. Upon cleavage by the complement C5 
convertase enzymes, the C5a fragment is generated and subsequently released (top figure). Upon 
cleavage by the noncomplement enzymes, trypsin or a-thrombin, C5aa and C5ot5 fragments are 
generated that are not released but remain covalently bonded to the protease-activated C5 molecule 
(bottom figure). 
of these patients would be a  210,000 molecular weight form of trypsin-modified C5. 
The results presented in Fig. 9 not only confirm the previously published results of 
other investigators (21,  32-37)  but clearly indicate that  a  variety of physiologically 
important, noncomplement protease enzymes can utilize C5 as a  substrate resulting WETSEL AND KOLB  2045 
in the expression of C5a-like inflammatory reactivities. In fact, the data presented in 
Fig.  10  strongly  suggests  that  a-thrombin,  a  centrally  important  enzyme  in  the 
coagulation system, activates C5 to express C5a-like biological activities by a mecha- 
nism that is virtually indistinguishable from that described for trypsin. Although the 
precise  mechanism  by  which  these  noncomplement  enzymes,  other  than  trypsin, 
structurally modify C5 to mediate these reactions is currently unknown, the ability of 
these enzymes to activate C5 to express C5a-like reactivities should greatly broaden 
our concepts regarding the potential ability of C5 to act as a mediator of nonimmu- 
nological inflammatory reactions in a variety of physiological as well as pathological 
in vivo situations. 
Summary 
Experimental conditions required for the expression of maximum C5  activation 
upon limited trypsin hydrolysis were determined to be 0.008 mol of trypsin/tool C5 
in a  reaction mixture containing  1 mg C5/ml  veronal-buffered saline incubated at 
37°C  for 30  rain.  Employing these optimal  incubation conditions, the primary or 
preferred site of trypsin hydrolysis of the C5a-ehain  resulted in  the production of 
C5al (molecular weight, 90,000) and C5~ (molecular weight, 25,000) fragments that 
remained disulfide bonded to the modified C5 molecule (C5'try).  Detailed structural- 
functional  analyses clearly indicated  the  trypsin-mediated conversion of the  C5a- 
chain to C5al and C5a5 was responsible for the acquisition of neutrophil lysosomal 
enzyme-releasing and chemotactic activities. Gel filtration column chromatography 
under physiological ionic strength, pH  7.4, or in the presence of 0.2%  SDS further 
demonstrated that  at least 90% of the total recoverable CSa-like biological activity 
was mediated by the 210,000 molecular weight forms of trypsin-modified C5. Other 
physiologically relevant,  noncomplement  protease  enzymes  (a-thrombin,  plasmin, 
and elastase) also activated C5 to express C5a-like reaetivities. Analysis of a-thrombin- 
induced, C5a-chain cleavage events by SDS-polyacrylamide slab gel eleetrophoresis 
indicated  that  the  mechanism  of a-thrombin-activation  of C5  is  similar  to  that 
described  for trypsin.  Reconciliation of this  novel mechanism  of C5  activation by 
trypsin with previously published results, and a discussion of  the biological significance 
of noncomplement enzyme-mediated activation of C5  as it might relate to inflam- 
matory processes in vivo, was presented. 
Reeeived  for publication 9 August  1982 and in revised  form 24January 1983. 
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